Cutaneous T Cell Lymphoma (CTCL) Clinical Trials in Tianjin, Tianjin Municipality
2 recruitingTianjin, Tianjin Municipality, China
Showing 1–2 of 2 trials
Recruiting
Phase 2
JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas
Lymphoma, T-CellT-LGL LeukemiaNK-LGL Leukemia+7 more
Institute of Hematology & Blood Diseases Hospital, China48 enrolled2 locationsNCT06716658
Recruiting
Phase 1
A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological Malignancies
Peripheral T Cell LymphomaCutaneous T Cell Lymphoma (CTCL)NHL (Non-Hodgkin Lymphoma)
Tianjin Medical University Cancer Institute and Hospital24 enrolled1 locationNCT06914037